Carisma Therapeutics Shakes Things Up: A Strategic Restructuring to Prioritize Our Pipeline!
Welcome to today’s blog post where we will be discussing the recent strategic reprioritization announced by Carisma Therapeutics Inc. This news involves the discontinuation of the development of CT-0525 and a significant reduction in the company’s workforce by 34%. As a result, Carisma will be reallocating its resources towards the advancement of their in vivo…